Approval · Notice of Compliance 17815 · 2016
ACTONEL: Notice of Compliance 17815
Issued March 1, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17815
- Date
- March 1, 2016
- Company
- Warner Chilcott Canada CoMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph pertaining to risk factors for osteonecrosis of the jaw
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | Not yet assigned | — |
| ACTONEL DR | Not yet assigned | — |
Medicinal ingredients
- RISEDRONATE SODIUM 5 MG per TAB
- RISEDRONATE SODIUM 30 MG per TAB
- RISEDRONATE SODIUM 35 MG per TAB
- RISEDRONATE SODIUM 75 MG per TAB
- RISEDRONATE SODIUM 150 MG per TAB